Esperson

Each gram of Esperson Ointment contains, as active ingredient, 2.5 mg desoximetasone in a water-in-oil emulsion.
Excipients/Inactive Ingredients: Isopropyl myristate, wool alcohol ointment (consisting of wool alcohol, cetyl stearyl alcohol and white petrolatum), purified water.

The desoximetasone in Esperson Ointment is an active corticosteroid specially developed for topical application. It has pronounced anti-inflammatory, anti-allergic, antiexudative, antiproliferative and antipruritic effects.

Esperson ointment are indicated for the relief of the inflammatory and pruritic manifestation of corticosteroid responsive dermatoses.

Dosage is generally based on the following guidelines and is determined by the physician in accordance with individual requirements:
Esperson Ointment should be applied sparingly to affected skin areas once or twice, or if necessary three times daily.
If possible, Esperson Ointment should be rubbed gently into the skin. After skin lesions have improved, the frequency of application may be reduced, for example, from twice to one daily.
Application over large areas (more than approximately 10% of body surface) and prolonged therapy (longer than approximately 4 weeks) should be avoided.
Both carry a risk of systemic corticosteroid effects; in addition, prolonged therapy is also associated with a risk of more pronounced local effects (see Adverse Reactions).
Dosage mistakes: Short-term deviations from the scheduled dose (application over too large an areas or in excessive amounts, too frequent application, or a single missed dose) will not lead to harmful effects. Please consult the physician if these occur.

Esperson Ointment must not be used on the eyes (see also Precautions) and in patients with hypersensitivity to desoximetasone, other corticosteroids of the betamethasone type, or any of the preservatives or excipients (see Description).
Esperson Ointment contains a paraffin, which can cause leaking or breaking of latex condoms. Contact between Esperson Ointment and latex condoms must, therefore, be avoided, because the protection afforded by the condoms may otherwise be lost.
Patients with skin reactions resulting from vaccinations, cutaneous manifestations of tuberculosis, syphilis, viral infections (for example chickenpox), rosacea, and perioral dermatitis, must not use topical corticosteroids such as Esperson Ointment, because there is a risk that the condition may deteriorate.
Use in Pregnancy and Lactation: Due to the risk of absorption of desoximetasone, application of Esperson Ointment over extensive areas is contraindicated during pregnancy or lactation.
However, if there are compelling medical reasons, Esperson Ointment may be applied to small areas of skin.

Visual disturbance may be associated with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR).
Esperson Ointment must only be used in infants or children under six years of age if there are compelling medical reasons, since in these age groups the risk of systemic effects due to corticosteroid absorption (for example growth retardation) is increased. If use is unavoidable, application must be limited to the minimum dose required for successful treatment.
In adult, it may in exceptional circumstances be necessary to apply Esperson Ointment over large areas of skin. In such cases, particularly in prolonged use, the possibility of adrenal suppression must be taken into account. Therefore patients should be evaluated periodically for evidence of HPA (hypothalamic-pituitary-adrenal) axis suppression by using the urinary free cortisol and ACTH stimulation test. If this occurs, it may be necessary to discontinue Esperson Ointment gradually or to substitute a less potent steroid.
Over the course of time, increased intra-ocular pressure can develop if small doses of topical corticosteroids (to include Esperson Ointment) come into repeated contact with the conjunctival sac. For this reason, prolonged application of Esperson Ointment in the immediate vicinity of the eyes. If irritation develops, topical corticosteroid should be discontinued and appropriate therapy instituted.
Topical corticosteroids such as Esperson Ointment must only be used for symptomatic therapy of bacterial and/or mycotic skin infections in combination with concomitant antibacterial or antimycotic treatment.
If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Due to the risk of absorption of desoximetasone, application of Esperson Ointment over extensive areas is contraindicated during pregnancy or lactation.
However, if there are compelling medical reasons, Esperson Ointment may be applied to small areas of skin.

Folliculitis, hypertrichosis, acne, hyper-or-hypopigmentation, telangiectases, striae distensae, skin atrophy and skin maceration, burning, itching, irritation, dryness, perioral dermatitis, allergic contact dermatitis and secondary infection may develop in the region of treated skin areas.
These effects occur particularly when treatment is prolonged and occlusive dressings are used. Esperson Ointment leads to local hypersensitivity reactions of the skin in rare cases only. Systemic corticosteroid effects may occur if Esperson Ointment is used over large areas, for prolonged periods (see also Dosage & Administration) or under occlusive dressings.
Metabolism and nutrition disorders: Unknown: hyperglycemia.
Eye disorders: Unknown: blurred vision, chorioretinopathy.
Please consult a physician if any of the adverse effects listed or any other undesired effects or unexpected changes (for example new skin changes) is noticed.

Store below 30°C.

Topical Corticosteroids

D07AC03 - desoximetasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.

K